It has been assumed that the uptake of long chain fatty acids (LCFAs) into skeletal muscle and the heart muscle, 2 as well as other tissues, occurred via passive diffusion. In recent years our work has shown that the LCFA uptake into skeletal muscle is a highly regulated process. The use of giant sarcolemmal vesicles obtained from skeletal muscle and heart has been used to demonstrate that LCFA uptake into these tissues occurs via a proteinmediated mechanism involving the 40 kDa plasma membrane associated fatty acid binding protein (FABPpm) and the 88 kDa fatty acid translocase, the homologue of human CD36 (FAT/CD36). Both are ubiquitously expressed proteins and correlate with LCFA uptake into heart and muscle, consistent with the known differences in LCFA metabolism in these tissues. It has recently been found that FAT/CD36 is present in an intracellular (endosomal) compartment from which it can be translocated to the plasma membrane within minutes by muscle contraction and by insulin, to stimulate LCFA uptake. In rodent models of obesity and type 1 diabetes LCFA uptake into heart and muscle is also increased, either by permanently relocating FAT/CD36 to the plasma membrane without altering its expression (obesity) or by increasing the expression of both FAT/CD36 and FABPpm (type 1 diabetes). Chronic leptin treatment decreases LCFA transporters and transport in muscle. Clearly, recent evidence has established that LCFA uptake into heart and muscle is regulated acutely and chronically.
they may be protonated, as the ionization constant (pKa) in the phospholipid bilayer environment is 7.6, while in the physiologic aqueous environment the pKa is 4.5 (Hamilton 1994) . Because the movement of ionized LCFAs is slow and the movement or 'flip-flop' of non-ionized LCFAs from one leaflet to another in the plasma membrane is very rapid (Gutnecht 1988 , Schmider et al. 2000 . Hamilton & Kamp (1999) have proposed that LCFAs enter the cell by (i) first absorbing to the plasma membrane, (ii) then protonating within the membrane, (iii) followed by a rapid flip-flop within the membrane and (iv) finally, desorbing into the cytosolic space. In this scheme protein mediated LCFA uptake is not required as this would slow the movement of LCFAs into the cell. However, Schaffer (2002) has recently pointed out several problems: (i) rapid rates of flip-flop, deduced from pH sensitive fluorescent dyes, are highly dependent on the diameter of the unilaminar vesicles, with changes in t 1/2 ranging from 23 ms in unilaminar vesicles (100 nm diameter) (Kamp et al. 1995) to t 1/2 of 60 s in clonal pancreatic beta-cells (20 lm diameter) , (ii) supraphysiological LCFA concentrations have been used which could overwhelm other mechanisms involved in transferring LCFAs across the plasma membrane, (iii) changes in the cellular acidification and alkalinization are indirect measures of the movement of LCFAs, and (iv) structurally simple synthetic phosphatidylcholine vesicles may not provide the same barrier to LCFA movement as those found in biologic membranes composed of complex lipids and proteins. Nevertheless, in some biologic membrane vesicles (erythrocyte ghost membranes) rapid rates of flip-flop are found and these rates are not protease sensitive (Kleinfeld et al. 1998) , suggesting that proteins are not involved in moving LCFAs across erythrocyte ghost membranes. However, the apparent absence of a protein-mediated LCFA uptake system in erythrocyte ghost membranes does not necessarily mean that a protein-mediated LCFA uptake system is absent in other tissues, especially those with different functions. In particular, skeletal muscle and heart are metabolically very active and can easily alter their metabolic rates. Therefore, in these tissues a rapidly adjustable LCFA transport system may well be needed.
LCFAs cross the sarcolemma via a protein-mediated mechanism
In the early 1980's Abumrad et al. (1981) showed that adipocyte LCFA uptake was saturable and appeared to involve proteins located at the plasma membrane. In subsequent years others provided supportive evidence for this concept (DeGrella & Light 1980 , Stremmel et al. 1985 , Schwieterman et al. 1988 , Stremmel 1988 , Sorrentino et al. 1989 , Stremmel 1989 , Storch et al. 1991 , Harmon et al. 1992 , Schaffer & Lodish 1994 . In all of these foregoing studies, in which saturation kinetics of LCFA uptake has been shown, there was a very major limitation. Specifically, in adipocytes, hepatocytes or cardiac myocytes the simultaneous LCFA metabolism confounds the determinations of LCFA 'uptake' rates across the plasma membrane. Thus, there had long been a concern that the saturation kinetics of LCFA uptake in these preparations was not because of rates of LCFA uptake across the plasma membrane, but instead, reflected some limitation(s) in LCFA metabolism. Therefore, it has been necessary to adjust the fatty acid uptake rates for the confounding effects of fatty acid metabolism, but it has not been possible to fully determine the adequacy of such corrections. Ideally, transport studies should be performed in the absence of any metabolism of the substrate, so as to not confound the rate of transport across the plasma membrane. There are two ways in which to effectively eliminate the confounding effects of substrate metabolism: by using a non-metabolizable analog or by using membrane preparations devoid of organelles and enzymes which facilitate the activation, oxidation and/or storage of the substrate.
We sought a vesicle preparation, that a) could be prepared from biological tissues and b) in which LCFA transport across the plasma membrane is divorced from subsequent LCFA metabolism. For these purposes the giant sarcolemmal vesicles used in some of our other work (McCullagh et al. 1996) appeared to provide an excellent model. Our (Bonen et al. 1998 , Luiken et al. 1999 ) characterization studies revealed a number of important features of the giant vesicles: they are large (10-15 lm diameter), are oriented 100% right-sideout, contain no functional mitochondria, and LCFAs taken up into the giant vesicles are not metabolized. Most critically, the giant vesicles contain large quantities of the 16 kDa cytoplasmic fatty acid binding protein (FABPc) which acts as a metabolic sink. We (Bonen et al. 1998 , Luiken et al. 1999 ) also demonstrated that LCFA uptake across the plasma membrane occurred via a protein-mediated system, as LCFA uptake was inhibited by protein modifying agents and inhibitors of selected LCFA transport proteins (Fig. 1a) . All the LCFA taken up into the vesicle was recovered as LCFA, with none being metabolized (Fig. 1b) . LCFA transport kinetics in heart and skeletal muscles revealed that the Km was similar in these tissues (6-9 nm unbound palmitate), but that the V max was 10-fold greater in heart compared with skeletal muscle (Luiken et al. 1999) (Fig. 1c) . Palmitate uptake rates in the heart, and red and white muscle giant vesicles (heart >> red muscle > white muscle) correlated well with the plasmalemmal LCFA transporters (Luiken et al. 1999) . Thus, the rates of LCFA uptake into muscle cells was directly proportional to the LCFA metabolizing capacity of different types of muscle cells. This also suggests that the rate of entry of LCFAs into the myocyte may be a rate limiting step in LCFA metabolism. These studies were pivotal in advancing our understanding of LCFA transport in muscle and heart, providing a model system (giant sarcolemmal vesicles) in which rates of LCFA uptake could be determined in the complete absence of LCFA metabolism.
It should be noted that for convenience of terminology, the protein-mediated LCFA uptake system has been termed a fatty acid transport system, although it is unlikely that the process of moving fatty acids across the plasma membrane involves pore formation as occurs with glucose transporters. It is more likely that LCFA traverse the plasma membrane via binding to one or more proteins, which then provides a transport-like system. Moreover, the presence of a protein-mediated mechanism does not negate the fact that a proportion of fatty acids will also diffuse across the plasma membrane.
LCFA transport proteins
At about the time that we were developing procedures to measure LCFA uptake by giant vesicles, a number of LCFA transporters were also identified. To date, however, little is known about their function and their regulation. Schaffer & Lodish (1994) , using an expression cloning approach, discovered an apparent long chain fatty acid transport protein (FATP) in adipocytes. Subsequently, it was shown that there is a family of these FATPs (FATP1-5), that are expressed in a tissue-specific manner (Schaffer & Lodish 1994 , Schaap et al. 1997 , Hirsch et al. 1998 . Although some evidence has linked the expression of FATP with increased rates of LCFA uptake by respiring cells (Schaffer & Lodish 1994 , Faergeman et al. 1997 , Stuhlsatz-Krouper et al. 1998 , Gargiulo et al. 1999 , there is some doubt as to whether FATP is actually an LCFA transporter. We observed an inverse relationship between LCFA transport and plasma membrane FATP1 (Luiken et al. 1999) . Other recent work has indicated that FATP is a peroxisomal very long-chain acyl CoA synthetase (VLCS) (Watkins et al. 1998 , Coe et al. 1999 .
Fatty acid transport protein
Plasma membrane associated fatty acid binding protein Stremmel et al. (1985) first demonstrated the existence of a 40 kDa plasma membrane-bound fatty acid binding protein (FABPpm) on the surface of liver cells [note: this protein differs from the 16 kDa cytosolic fatty acid binding protein (FABPc)]. Antibodies raised against this 40 kDa protein, isolated from liver plasma membranes, inhibited LCFA uptake (Stremmel et al. 1985 , Diede et al. 1992 . Surprisingly, the amino acid sequence of FABPpm is identical to mitochondrial aspartate aminotransferase (mAspAT) (Stump et al. 1993) . However, when 3T3-L1 fibroblasts are transfected with mAspAT cDNA, FABPpm is expressed (a) LCFA transport is inhibited by protein modifying agents, reduced temperature and reactive esters of oleate (SSO) and antibody to FABPpm. Protein mediated LCFA uptake is specific for long chain LCFAs, as palmitate is displaced by excess oleate (18 : 1) uptake but not by a short chain fatty acid (octanoate) nor glucose. (b) LCFA taken up into the vesicle (uptake) is present in the lumen of the vesicle (cytosol) as unmetabolized fatty acid (FA), as no fatty acid metabolites (PL: phospholipids; MAG: monoacylglycerols; DAG: diacylglycerols; TAG: triacylglycerols) nor oxidation product (CO 2 ) were detected. (c) Palmitate transport kinetics in giant vesicles from heart and skeletal muscle (Km in heart and muscle is similar 6-9 nm unbound palmitate, whereas V max in heart is 10-fold greater). Data in Figure 1a -c redrawn from (Bonen et al. 1998 , Luiken et al. 1999 ).
on the cell surface and LCFA uptake is increased (Isola et al. 1995) . Only a single FABPpm mRNA is found in cells that express largely mAspAT in mitochondria or FABPpm at the plasma membrane (Bradbury & Berk 2000) . FABPpm is expressed in most metabolic tissues examined to date (Berk et al. 1996 , Berk et al. 1997 , Bonen et al. 1998 , Luiken et al. 1999 , Turcotte et al. 2000 .
Fatty Acid Translocase
Almost 20 years ago Abumrad et al. (1981 Abumrad et al. ( , 1984 demonstrated that the uptake of LCFAs in adipocytes occurred via a protein mediated mechanism. Subsequently, they showed that sulfo-N-succinimidyl esters of fatty acids would bind to an 88-kDa protein in the adipocyte plasma membrane, which coincided with the nearly complete abolishment of LCFA transport (Harmon et al. 1991 , Harmon et al. 1992 , Harmon & Abumrad 1993 . This led directly to the discovery of the 88 kDa transporter fatty acid translocase (FAT) which was homologous to human CD36 . For this reason this protein is commonly referred to as FAT/CD36 and has a predicted molecular weight of 53 kDa. The observed molecular weight of 88 kDa is because of its extensive glycosylation . When fibroblasts, which do not express the FAT/CD36 gene and which do not exhibit extensive LCFA uptake, were transfected with the FAT/CD36 gene, LCFA uptake was increased in proportion to the amount of FAT/CD36 protein expressed (Ibrahimi et al. 1996) . It must also be pointed out that FAT/CD36 has many other well documented functions besides transporting LCFAs into muscle tissue (for review see (Febbraio et al. 2001) ).
It is quite clear now that there are at least two key LCFA transport proteins, FABPpm and FAT/CD36. The role of FATP1 in transporting LCFAs across the plasma membrane in muscle and heart is presently unclear. Whether both FAT/CD36 and FABPpm are required to transport LCFAs is not yet clear, but is suggested in some of our work (Luiken et al. 1999) . FABPpm and especially FAT/CD36 are expressed in relation to the oxidative capacities of heart and skeletal muscle (Fig. 2) .
Mechanisms regulating LCFA transport into skeletal muscles
Given that LCFA uptake occurred via a protein mediated mechanism and that several LCFA transport proteins had been identified, it was important to determine whether LCFA uptake was regulatable either (i) by altering the expression of the transport proteins and/or (ii) by altering the subcellular localization of the LCFA transporters. For these purposes a number of diverse experimental models were used.
Chronic regulation of LCFA transport and transporters
In the first of these studies we used chronic electrical stimulation of muscle (24 h day )1 , for 7 days). This procedure had previously been used to upregulate glucose and lactate transporters in our work. The advantage is that the animals tolerate this seemingly harsh intervention very well, and the contralateral muscles that are not stimulated serve as an ideal control. We found that chronic muscle stimulation increased the expression of FAT/CD36 and this was associated with an increase in LCFA transport (Fig. 3 ) . Subsequent work demonstrated that FABPpm is increased, although much more modestly (Benton & Bonen, unpublished data) . In other studies of increased muscle contraction (exercise training) the expression of FABPpm was increased in rodents ) and humans (Kiens et al. 1997) . The effects on FAT/CD36 were not examined in these studies, nor were concomitant changes in LCFA transport determined.
We have recently examined whether LCFA transport was reduced in chronic (2 week) leptin-treated animals. Leptin limits the accumulation of intramuscular triacylglycerol depots ) by stimulating the rates of LCFA oxidation and triacylglycerol hydrolysis, while also reducing the rate of LCFA esterification in muscle (Muoio et al. 1997 , Muoio et al. 1999 , Steinberg & Dyck 2000 . Therefore, we speculated that lowering LCFA uptake could also contribute to limiting LCFA metabolism. In the 2 week leptin-treated rats, we observed that LCFA transport was reduced along with a reduction in plasmalemmal FAT/CD36 (primarily) and Figure 2 Western blots of FAT/CD36 (88 kDa) and FABPpm (40 kDa) in heart (H), red (RG) and white gastrocnemius (WG), and soleus (S) muscles (Bonen, unpublished data).
FABPpm (Steinberg et al. 2002) . This suggests that limiting the entry of LCFAs into the myocyte over the long term may also be part of a 'leptin-strategy' designed to reduce the intramuscular triacylglycerol depots.
In animal models of obesity and type 1 diabetes there is an increase in LCFA metabolism (i.e. increase in muscle LCFA esterification and/or LCFA oxidation). We therefore speculated that in these models there may well be an accompanying increase in LCFA flux into muscle. In a model of type 1 diabetes, we found that muscle and heart LCFA transport was increased due the increased expression of LCFA transporters, primarily FAT/CD36, which resulted in more of the transporters being located at the plasma membrane (Fig. 4) (Luiken et al. 2002) . Similarly, in obese Zucker rats we also found that LCFA uptake was increased, but the underlying mechanism differed. Specifically, LCFA transporter expression was not altered; rather, the localization of FAT/CD36 at the plasma membrane was increased (Fig. 5) (Luiken et al. 2001 ). As we had previously found that FAT/CD36 was present in an intracellular pool as well as at the plasma membrane, it appears that a portion of the intracellular depot was permanently re-located to the plasma membrane.
These physiologic studies showing changes in LCFA transport in relation to concomitant changes in FAT/ (n ¼ 4-6 animals; transport experiments were conducted at submaximal concentrations of palmitate). *P < 0.05, type 1 diabetes vs. control data redrawn from (Luiken et al. 2002a ).
Ó 2003 Scandinavian Physiological Society CD36 and FABPpm are also supported by studies in which LCFA transporter expression has been genetically altered. In transgenic mice that overexpress FAT/CD36 in muscle, circulating fatty acid levels were reduced. There was also a large increase in fatty acid oxidation, but only during muscle contraction , when the muscle's energetic demands were increased. Conversely, in FAT/CD36 null mice, circulating fatty acid levels are increased (Febbraio et al. 1999) while the tissue uptake of BMIPP, an indirect measure of fatty acid transport, is reduced in heart, muscle and adipose tissue (Coburn et al. 2000) . Comparable studies in which FABPpm has been altered have not yet been published. However, we have transfected soleus muscle with FABPpm cDNA and can demonstrate that this also increases muscle plasmalemmal FABPpm and LCFA uptake (Clarke & Bonen, unpublished data) . Collectively, our studies have established that LCFA transport into the muscle can be regulated by altering the plasma membrane content of LCFA transport proteins. Such alterations in these transporters are achieved either (i) by increasing their expression (chronic muscle stimulation, exercise training, type 1 diabetes, (ii) by repressing their expression (2-week leptin treatment), or (iii) by permanently relocating some of the transport proteins (FAT/CD36) from an intracellular depot to the plasma membrane (obesity).
Acute regulation of LCFA transport and transporters
Based on our work showing that LCFA oxidation was increased only during muscle contraction, despite the overexpression of FAT/CD36, we raised the question as to whether it was possible to translocate FAT/CD36 in muscle from an intracellular compartment to the sarcolemma. Until that time the possibility of an acute regulation of LCFA transport had not been considered, as the prevailing dogma had been that LCFA delivery (bloodflow · LCFA concentration) largely regulated LCFA metabolism. Moreover, it was not known whether there was an available intracellular depot of LCFA transporters that could be translocated.
We opted to use a muscle contraction model to ascertain whether LCFA transport was acutely regulated. Stimulation of the sciatic nerve, which causes all rat hindlimb muscles to contract, provided a controlled means of increasing the demand for LCFAs. At selected time points during 30 min of muscle stimulation, as well as time points after the muscle stimulation had stopped, we prepared giant vesicles and performed transport studies . This work showed that with muscle contraction fatty acid transport was increased rapidly (Fig. 6 ). Kinetic studies of fatty acid uptake showed that V max was increased while there was no change in Km. From fractionation studies of muscle tissue, we showed that FAT/CD36 is present in both an intracellular pool and in the plasma membrane (Fig. 6) . Interestingly, with muscle contraction a portion of this intracellular pool was translocated to the plasma membrane, thereby increasing fatty acid uptake acutely (Fig. 6) . During the post-contraction recovery period fatty acid transport returned to control levels while concomitantly FAT/CD36 was internalized from the plasma membrane . Thus, our studies have established that it is indeed possible to regulate LCFA transport within a matter of minutes, revealing a novel means of regulating LCFA metabolism in skeletal muscle.
In more recent work we (Luiken et al. 2002) have shown that insulin also translocates FAT/CD36 (Fig. 7) , and this occurs via the PI3-kinase signalling pathway. in skeletal muscles from lean and obese Zucker rats. (n ¼ 6-7 animals; transport experiments were conducted at submaximal concentrations of palmitate) *P < 0.05, Obese Zucker rats vs. control data redrawn from (Luiken et al. 2001 ).
The effects of insulin and muscle contraction on fatty acid uptake by intact muscle are additive , and this may suggest that there are separate intracellular pools of FAT/CD36 that are sensitive to insulin-or contraction-activated signals. Such insulin and contraction-sensitive intracellular transport protein pools have already been identified for GLUT4 (Lemieux et al. 2000) . We also have preliminary evidence that insulin regulates the expression of FAT/CD36 (Chabowski & Bonen, unpublished data) . These recent studies in our laboratory have revealed a completely novel function for insulin.
It is clear from our recent work that fatty acid transport is regulated acutely within minutes by muscle contraction and by insulin, and that the regulation involves the cellular redistribution of FAT/CD36. However, whether FABPpm is redistributed by these physiologic stimuli is not known.
Conclusion
With the characterization of the giant sarcolemmal vesicle preparation as a suitable model for LCFA transport studies by our group, and the identification of several LCFA transport proteins by others, we have been able to demonstrate that LCFA transport across the plasma membrane in skeletal muscle occurs via a protein-mediated process. Yet, the mechanism of moving LCFAs across the sarcolemma via one or more transport proteins remains obscure. It is however now clear that the well known increments in LCFA metabolism that are observed with exercise training and during muscle contraction are due, in part, to the enhanced uptake of LCFAs across the plasma membrane. Chronic adaptations in LCFA transport involve either changes in the levels of LCFA transport protein expression or a permanent relocation of these transporter within the myocyte, both mechanisms serve to increase the available LCFA transporters at the plasma membrane. Acute upregulation of LCFA transport can be induced by temporarily translocating the LCFA transporter FAT/ CD36 to the plasma membrane. Another very important observation is the upregulation of LCFA transport in skeletal muscle in obesity. This may contribute to an excessive influx of LCFAs which cannot be oxidized, resulting in the accumulation of intramuscular triacylglycerols (Pan et al. 1997) and long chain acyl CoA esters (Ellis et al. 2000) , both of which have been linked to the development of insulin resistance in muscle (Pan et al. 1997 , Ellis et al. 2000 . Clearly, an understanding of how LCFA transporters are regulated will be important to account for changes in LCFA metabolism in healthy individuals and those with insulin resistance.
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